1. Awwad M, North RJ (1988) Cyclophosphamide (Cy)-facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunol 65: 87
2. Awwad M, North RJ (1990) Radiosensitive barrier to T-cell-mediated adoptive immunotherapy of established tumors. Cancer Res 50: 2228
3. Chou T, Shu S (1987) Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma. J Immunol 139: 2103
4. Dillman RO, Oldham RK, Tauer KW, Orr DW, Barth NM, Blumenschein G, Arnold J, Birch R, West WH (1991) Continuous interleukin-2 and lymphokine-activated killer cells for advanced cancer: a National Biotherapy Study Group trial. J Clin Oncol 9: 1233
5. Hermann GG, Geertsen PF, Maase H, Steven K, Andersen C, Hald T, Zeuthen J (1992) Recombinant interleukin-2 and lymphokine-activated killer cell treatment of advanced bladder cancer, clinical results and immunological effects. Cancer Res 52: 726